Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka

The clinical application of anthracycline chemotherapy is hindered due to the cumulative dose-dependent cardiotoxicity followed by the oxidative stress initiated during the mechanism of action of anthracyclines. Due to a lack of prevalence data regarding anthracycline-induced cardiotoxicity in Sri L...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2023-03, Vol.23 (1), p.210-210, Article 210
Main Authors: Sandamali, Jayasinghe Arachchige Nirosha, Hewawasam, Ruwani Punyakanthi, Fernando, Madappuli Arachchige Chaminda Sri Sampath, Jayatilaka, Kamani Ayoma Perera Wijewardana
Format: Article
Language:English
Subjects:
Age
Anthracycline
Anthracyclines
Antibiotics, Antineoplastic
Biochemical analysis
Biomarkers
Brain natriuretic peptide
Breast cancer
Breast cancer patients
Breast Neoplasms
Calcium-binding protein
Cancer
Cancer therapies
Cardiotoxicity
Care and treatment
Chemotherapy
Cross-Sectional Studies
Diagnosis
Dosage and administration
Doxorubicin
Drugs
Echocardiography
EKG
Electrocardiogram
Electrocardiography
Enzymes
Epirubicin
Female
Health aspects
Heart
Heart failure
Hospitals, Teaching
Humans
Informed consent
Methods
NT-proBNP
Oxidative stress
Patient outcomes
Patients
Quality of Life
Questionnaires
Risk factors
Sri Lanka
Statistical analysis
Teaching hospitals
Troponin I
Variance analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clinical application of anthracycline chemotherapy is hindered due to the cumulative dose-dependent cardiotoxicity followed by the oxidative stress initiated during the mechanism of action of anthracyclines. Due to a lack of prevalence data regarding anthracycline-induced cardiotoxicity in Sri Lanka, this study was conducted to determine the prevalence of cardiotoxicity among breast cancer patients in Southern Sri Lanka in terms of electrocardiographic and cardiac biomarker investigations. A cross-sectional study with longitudinal follow-up was conducted among 196 cancer patients at the Teaching Hospital, Karapitiya, Sri Lanka to determine the incidence of acute and early-onset chronic cardiotoxicity. Data on electrocardiography and cardiac biomarkers were collected from each patient, one day before anthracycline (doxorubicin and epirubicin) chemotherapy, one day after the first dose, one day and six months after the last dose of anthracycline chemotherapy. Prevalence of sub-clinical anthracycline-induced cardiotoxicity six months after the completion of anthracycline chemotherapy was significantly higher (p 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-023-10673-0